Baek, H.-S.; Ha, J.; Ha, S.; Bae, J.S.; Jung, C.K.; Lim, D.-J.
Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea. Curr. Oncol. 2023, 30, 3020-3031.
https://doi.org/10.3390/curroncol30030229
AMA Style
Baek H-S, Ha J, Ha S, Bae JS, Jung CK, Lim D-J.
Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea. Current Oncology. 2023; 30(3):3020-3031.
https://doi.org/10.3390/curroncol30030229
Chicago/Turabian Style
Baek, Han-Sang, Jeonghoon Ha, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung, and Dong-Jun Lim.
2023. "Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea" Current Oncology 30, no. 3: 3020-3031.
https://doi.org/10.3390/curroncol30030229
APA Style
Baek, H.-S., Ha, J., Ha, S., Bae, J. S., Jung, C. K., & Lim, D.-J.
(2023). Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea. Current Oncology, 30(3), 3020-3031.
https://doi.org/10.3390/curroncol30030229
